IPSEN, OOO
- Country
- π«π·France
- Ownership
- -
- Established
- 1929-01-01
- Employees
- 5.7K
- Market Cap
- $9.8B
- Website
- https://www.ipsen.com/
A Study Describing Scratch and Sleep Patterns in Patients With Primary Biliary Cholangitis (Luminaria)
- Conditions
- Primary Biliary Cholangitis
- First Posted Date
- 2025-07-03
- Last Posted Date
- 2025-07-03
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 30
- Registration Number
- NCT07049887
A study of IPN10200 for the treatment of cervical dystonia in adults
- First Posted Date
- 2025-05-12
- Last Posted Date
- 2025-06-24
- Lead Sponsor
- Ipsen Innovation
- Target Recruit Count
- 91
- Registration Number
- 2024-519248-34-00
- Locations
- π¨πΏ
Fakultni Nemocnice U Sv Anny V Brne, Brno-Stred, Czechia
π¨πΏNeurohk s.r.o., Chocen, Czechia
π¨πΏUniversity Hospital Olomouc, Olomouc, Czechia
A Study of the Blood Levels of Palovarotene in Participants With Abnormal Liver Function Compared to Healthy Adult Participants After Intake of a Single Dose
- First Posted Date
- 2025-04-03
- Last Posted Date
- 2025-06-22
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 32
- Registration Number
- NCT06908954
- Locations
- πΊπΈ
ERG - Clinical Pharmacology of Miami, Miami, Florida, United States
πΊπΈOrlando Clinical Research Center, Orlando, Florida, United States
πΊπΈAmerican Research Corporation/Texas Liver Institute, San Antonio, Texas, United States
A Study Observing the Long-term, Effectiveness and Safety of Odevixibat (Bylvay) in Patients With Alagille Syndrome (ALGS) Who Are Receiving Ongoing Treatment
- Conditions
- Alagille Syndrome
- First Posted Date
- 2025-02-27
- Last Posted Date
- 2025-06-22
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 30
- Registration Number
- NCT06850038
- Locations
- πΊπΈ
Proactive El Paso,LLC, El Paso, Texas, United States
πΊπΈNYU Langone - NYU Grossman School of Medicine, New York, New York, United States
A Study to Assess a New Medicine Called IPN01195 When Administered Alone in Adults With Advanced Solid Tumours
- First Posted Date
- 2025-02-18
- Last Posted Date
- 2025-06-22
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 85
- Registration Number
- NCT06833008
- Locations
- πΊπΈ
START Mid-West, Grand Rapids, Michigan, United States
πΊπΈSarah Cannon Research Institute (SCRI) - Nashville, Nashville, Tennessee, United States
πΊπΈMary Crowley Cancer Research Centers - Medical City Hospital - Dallas, Dallas, Texas, United States
A Study of Elafibranor in Adult Japanese Participants With Primary Biliary Cholangitis (PBC)
- First Posted Date
- 2024-12-12
- Last Posted Date
- 2025-06-22
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 18
- Registration Number
- NCT06730061
- Locations
- π―π΅
Nippon Medical School - Chiba Hokusoh Hospital, Chiba, Japan
π―π΅Fukushima Medical University Hospital, Fukushima, Japan
π―π΅Chugoku Rosai Hospital, Hiroshima, Japan
A Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic Migraine in Adults
- Conditions
- Episodic MigraineChronic Migraine
- Interventions
- First Posted Date
- 2024-10-03
- Last Posted Date
- 2025-06-22
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 641
- Registration Number
- NCT06625060
- Locations
- πΊπΈ
MedStar Neurosciences and Rehabilitation Research Network, Baltimore, Maryland, United States
πΊπΈMD First Research - Chandler, Chandler, Arizona, United States
πΊπΈProfound Research. LLC - NCSC, Carlsbad, California, United States
A Study Observing Everyday Effectiveness and Safety of the Drug Elafibranor in Participants With Primary Biliary Cholangitis Who Are Receiving Ongoing Treatment
- Conditions
- Primary Biliary Cholangitis
- First Posted Date
- 2024-06-06
- Last Posted Date
- 2025-05-28
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 424
- Registration Number
- NCT06447168
- Locations
- πΊπΈ
Cedars-Sinai Medical Center, Los Angeles, California, United States
πΊπΈVirtua Center for Liver Disease - Cherry Hill, Cherry Hill, New Jersey, United States
π¬π§Queen's Medical Centre - Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid.
- Conditions
- Primary Biliary Cholangitis
- Interventions
- Other: Placebo
- First Posted Date
- 2024-04-25
- Last Posted Date
- 2025-06-22
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 69
- Registration Number
- NCT06383403
- Locations
- πΊπΈ
Southern California Research Center, Coronado, California, United States
πΊπΈTopgraphy Health, Inc., Los Angeles, California, United States
πΊπΈUniversity of California, Davis, Sacramento, California, United States
Effects of Maintenance Cabozantinib+BSC Versus BSC in Children and AYA With Osteosarcoma
- Conditions
- OsteosarcomaOsteosarcoma in ChildrenOsteosarcoma in Adolescents and Young Adults
- Interventions
- Other: Best Supportive Care (BSC)
- First Posted Date
- 2024-04-02
- Last Posted Date
- 2025-06-22
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 90
- Registration Number
- NCT06341712
- Locations
- πΊπΈ
University of Southern California (USC) - Norris Cancer Hospital, Los Angeles, California, United States
πΊπΈStanford University and Lucile Packard Children's Hospital, Palo Alto, California, United States
πΊπΈUniversity of Florida Health Shands Children's Hospital, Gainesville, Florida, United States